International Journal of Clinical Oncology

, Volume 22, Issue 3, pp 541–547

Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey

  • Hideki Tokunaga
  • Fumiaki Takahashi
  • Hiroki Yamamoto
  • Tsuyoshi Honda
  • Takafumi Watanabe
  • Tadahiro Shoji
  • Toru Sugiyama
  • Hidekazu Yamada
  • Tomoe Tando
  • Kosuke Yoshinaga
  • Satoko Kagabu
  • Takeo Otsuki
  • Shogo Kin
  • Yoshihito Yokoyama
  • Satoshige Wagatsuma
  • Kazuyo Sato
  • Hirokazu Sato
  • Takashi Oishi
  • Yuji Yoshida
  • Tadashi Hayasaka
  • Toshihiko Matsui
  • Noriaki Imai
  • Hidekazu Nishigori
  • Hiroaki Shimokawa
  • Nobuo Yaegashi
  • Yoh Watanabe
Original Article

Abstract

Background

To prepare for a future clinical trial for improving the long-term prognosis of patients with uterine leiomyosarcoma (ULMS), we conducted a multi-institutional survey in the Tohoku region of Japan.

Methods

We conducted a retrospective cohort study between 2011 and 2014 in member institutions of the Tohoku Translational Research Center Development Network.

Results

A total of 53 patients with ULMS were registered in 31 institutions for the present survey. The median patient age was 56 years, 67.9% of the patients were postmenopausal, 88.7% had a performance status of 0 or 1, and only 6 patients (11.3%) showed preoperative evidence of malignancy. Although retroperitoneal lymphadenectomy was performed in only 26.4% of patients, 64.2% patients were identified as having FIGO stage 1 disease; 73.6% were eligible to undergo complete surgery. Among 36 patients who were treated with postoperative chemotherapy, 28 (77.8%) received docetaxel and gemcitabine combination therapy. The most frequent recurrence site was the lungs, and the median progression-free survival of all enrolled patients was 11.7 months. However, the median progression-free survival and the median overall survival in patients with stages III and IV disease were 3.4 and 11.4 months, respectively.

Conclusion

Although ULMS was associated with a high rate of complete or optimal surgery, the long-term prognosis was poor. Effective postoperative therapy should be developed to improve the long-term prognosis of patients with ULMS.

Keywords

Uterine leiomyosarcoma Tohoku region Retrospective survey 

References

  1. 1.
    Toro JR, Travis LB, Wu HJ (2006) Incidence patterns of soft tissue sarcomas, regardless of primary site, in the Surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer 119:2922–2930CrossRefPubMedGoogle Scholar
  2. 2.
    Nodal RR, Thoresen SO (1997) Uterine sarcomas in Norway 1956–1992: incidence, survival and mortality. Eur J Cancer 33:907–911CrossRefGoogle Scholar
  3. 3.
    Abeler VM, Royne O, Thoresen S et al (2009) Uterine sarcomas in Norway. a histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 54:355–364CrossRefPubMedGoogle Scholar
  4. 4.
    Giuntoli RL, Metzinger DS, DiMarco CS et al (2003) Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 89:460–469CrossRefPubMedGoogle Scholar
  5. 5.
    Sagae S, Yamashita K, Ishioka S et al (2004) Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology 67:33–39CrossRefPubMedGoogle Scholar
  6. 6.
    Kokawa K, Nishiyama K, Ikeuchi M (2006) Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990-2003). Int J Gynecol Cancer 16:1358–1363CrossRefPubMedGoogle Scholar
  7. 7.
    Akahira J, Tokunaga H, Toyoshima M et al (2006) Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma. Oncology 71:333–340CrossRefPubMedGoogle Scholar
  8. 8.
    Gadducci A, Landoni F, Sartori E et al (1996) Uterine liomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 62:25–32CrossRefPubMedGoogle Scholar
  9. 9.
    Mayerhofer K, Obermair A, Windbichler G et al (1999) Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 74:196–201CrossRefPubMedGoogle Scholar
  10. 10.
    Farid M, Ong WS, Tang MH et al (2013) The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease. Am J Clin Oncol 36:368–374CrossRefPubMedGoogle Scholar
  11. 11.
    Rauh-Hain JA, Oduyebo T, Diver EJ et al (2013) Uterine leiomyosarcoma: an updated series. Int J Gynecol Cancer 23:1036–1043CrossRefPubMedGoogle Scholar
  12. 12.
    Garcia C, Kubat JS, Fulton RS et al (2015) Clinical outcomes and prognostic marker in uterine leiomyosarcoma: a population-based cohort. Int J Gynecol Cancer 25:622–628CrossRefPubMedGoogle Scholar
  13. 13.
    Ricci S, Giuntoli RL, Eisenhauer E et al (2013) Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? Gynecol Oncol 131:628–629Google Scholar
  14. 14.
    Mancari R, Signorelli M, Gadducci A et al (2014) Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentris retrospective study of 140 patients. Gynecol Oncol 133:531–536CrossRefPubMedGoogle Scholar
  15. 15.
    Hensley ML, Ishill N, Soslow R et al (2009) Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 112:563–567CrossRefPubMedGoogle Scholar
  16. 16.
    Hensley ML, Blessing JA, Degeest K et al (2008) Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 109:323–328CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hensley ML, Blessing JA, Mannel R et al (2008) Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 109:329–334CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hensley ML, Wathen JK, Maki RG et al (2013) Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer 15:1555–1561CrossRefGoogle Scholar
  19. 19.
    Takano T, Niikura H, Ito K et al (2013) Feasibility study of gemcitabine and docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan. Int J Clin Oncol 19:897–905CrossRefPubMedGoogle Scholar
  20. 20.
    van der Graaf WT, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886CrossRefPubMedGoogle Scholar
  21. 21.
    Demetri GD, von Mehren M, Jones RL et al (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 34:786–793CrossRefPubMedGoogle Scholar
  22. 22.
    Schoffski P, Chawla S, Maki RG et al (2016) Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomized, open-label, multicenter, phase 3 trial. Lancet 16:1629–1637CrossRefGoogle Scholar
  23. 23.
    Tap WD, Jones RL, TineBA Van et al (2016) Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 388:488–497CrossRefPubMedGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2017

Authors and Affiliations

  • Hideki Tokunaga
    • 1
  • Fumiaki Takahashi
    • 2
  • Hiroki Yamamoto
    • 3
  • Tsuyoshi Honda
    • 4
  • Takafumi Watanabe
    • 5
  • Tadahiro Shoji
    • 6
  • Toru Sugiyama
    • 6
  • Hidekazu Yamada
    • 7
  • Tomoe Tando
    • 8
  • Kosuke Yoshinaga
    • 9
  • Satoko Kagabu
    • 10
  • Takeo Otsuki
    • 11
  • Shogo Kin
    • 12
  • Yoshihito Yokoyama
    • 13
  • Satoshige Wagatsuma
    • 14
  • Kazuyo Sato
    • 15
  • Hirokazu Sato
    • 16
  • Takashi Oishi
    • 17
  • Yuji Yoshida
    • 18
  • Tadashi Hayasaka
    • 19
  • Toshihiko Matsui
    • 20
  • Noriaki Imai
    • 21
  • Hidekazu Nishigori
    • 1
  • Hiroaki Shimokawa
    • 2
    • 22
  • Nobuo Yaegashi
    • 1
  • Yoh Watanabe
    • 2
    • 23
  1. 1.Department of Obstetrics and GynecologyTohoku University Graduate School of MedicineSendaiJapan
  2. 2.Clinical Research, Innovation and Education CenterTohoku University HospitalSendaiJapan
  3. 3.Department of Obstetrics and GynecologyOmagari Kousei Medical CenterOmagariJapan
  4. 4.Department of Obstetrics and GynecologyIwaki Kyoritsu HospitalIwakiJapan
  5. 5.Department of Obstetrics and GynecologyFukushima Medical UniversityFukushimaJapan
  6. 6.Department of Obstetrics and GynecologyIwate Medical University School of MedicineMoriokaJapan
  7. 7.Department of GynecologyMiyagi Cancer CenterNatoriJapan
  8. 8.Department of Obstetrics and GynecologyHirosaki National HospitalHirosakiJapan
  9. 9.Department of Obstetrics and GynecologySendai Medical CenterSendaiJapan
  10. 10.Department of Obstetrics and GynecologyNakadori General HospitalAkitaJapan
  11. 11.Department of Obstetrics and GynecologySendai City HospitalSendaiJapan
  12. 12.Department of Obstetrics and GynecologyTakeda General HospitalAizuwakamatsuJapan
  13. 13.Department of Obstetrics and GynecologyHirosaki University Graduate School of MedicineHirosakiJapan
  14. 14.Department of Obstetrics and GynecologyOsaki Citizen HospitalOsakiJapan
  15. 15.Department of Obstetrics and GynecologyIwate Prefectural Chubu HospitalKitakamiJapan
  16. 16.Department of Obstetrics and GynecologyJapanese Red Cross Akita HospitalAkitaJapan
  17. 17.Department of Obstetrics and GynecologyAomori Kousei HospitalAomoriJapan
  18. 18.Department of Obstetrics and GynecologyJapanese Red Cross Ishinomaki HospitalIshinomakiJapan
  19. 19.Department of Obstetrics and GynecologyNihonkai General HospitalSakataJapan
  20. 20.Department of Obstetrics and GynecologyNoshiro Kousei Medical CenterAkitaJapan
  21. 21.Department of Obstetrics and GynecologyHachinohe City HospitalHachinohe, AomoriJapan
  22. 22.Department of Cardiovascular MedicineTohoku University Graduate School of MedicineSendaiJapan
  23. 23.Department of Obstetrics and GynecologyTohoku Medical and Pharmaceutical UniversitySendaiJapan

Personalised recommendations